Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2009-02-05
2011-12-06
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S253040, C514S303000, C540S575000, C544S362000, C546S110000
Reexamination Certificate
active
08071588
ABSTRACT:
The present invention relates to novel compounds of Formula (I)and their use in the treatment of respiratory diseases, including anti-inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.
REFERENCES:
patent: 3755340 (1973-08-01), Hoehn et al.
patent: 3833594 (1974-09-01), Hoehn et al.
patent: 3840546 (1974-10-01), Hoehn et al.
patent: 3856799 (1974-12-01), Hoehn et al.
patent: 3925388 (1975-12-01), Hoehn et al.
patent: 3966746 (1976-06-01), Hoehn et al.
patent: 3979399 (1976-09-01), Hoehn et al.
patent: 6825184 (2004-11-01), Cirillo et al.
patent: 2007/0167485 (2007-07-01), Coe et al.
patent: 2007/0254913 (2007-11-01), Dunn et al.
patent: 1003419 (1977-01-01), None
patent: 0076035 (1985-12-01), None
patent: 00/15222 (2000-03-01), None
patent: WO 02/060900 (2002-08-01), None
patent: 02/081463 (2002-10-01), None
patent: 03/087064 (2003-10-01), None
patent: 2004/012684 (2004-02-01), None
patent: 2004/024728 (2004-03-01), None
patent: 2004/056823 (2004-07-01), None
patent: 2004/091482 (2004-10-01), None
patent: 2005/009362 (2005-02-01), None
patent: 2005/009439 (2005-02-01), None
patent: 2005/009440 (2005-02-01), None
patent: 2005/037224 (2005-04-01), None
patent: 2005/037280 (2005-04-01), None
patent: 2005/046586 (2005-05-01), None
patent: 2005/055940 (2005-06-01), None
patent: 2005/055941 (2005-06-01), None
patent: 2005/058892 (2005-06-01), None
patent: 2005/095407 (2005-06-01), None
patent: 2005/067537 (2005-07-01), None
patent: 2005/086873 (2005-09-01), None
patent: 2005/087236 (2005-09-01), None
patent: 2005/090348 (2005-09-01), None
patent: 2005/090352 (2005-09-01), None
patent: 2005/090353 (2005-09-01), None
patent: 2005/090354 (2005-09-01), None
patent: 2005/094251 (2005-10-01), None
patent: 2005/094834 (2005-10-01), None
patent: 2005/094835 (2005-10-01), None
patent: 2005/099706 (2005-10-01), None
patent: 2005/104745 (2005-11-01), None
patent: 2005/112644 (2005-12-01), None
patent: 2005/118594 (2005-12-01), None
patent: 2006/005057 (2006-01-01), None
patent: 2006/017767 (2006-02-01), None
patent: 2006/017768 (2006-02-01), None
patent: 2006/050239 (2006-05-01), None
patent: 2006/055503 (2006-05-01), None
patent: 2006/055553 (2006-05-01), None
patent: 2006/062883 (2006-06-01), None
patent: 2006/062931 (2006-06-01), None
patent: 2006/065755 (2006-06-01), None
patent: 2006/065788 (2006-06-01), None
patent: 2007/016639 (2007-02-01), None
patent: 2007/016650 (2007-02-01), None
patent: 2007/018508 (2007-02-01), None
patent: 2007/018514 (2007-02-01), None
patent: 2007/022351 (2007-02-01), None
patent: WO 2008/009735 (2008-01-01), None
Fryer and Jacoby, “Muscarinic Receptors and Control of Airway Smooth Muscle” Am J. Respir Crit Care Med; 1998; vol. 158 (5); pp. S154-S160).
Fryer, et al. “Effects of inflammatory cells on neuronal M2 muscarinic receptor function in the lung” Life Sciences; 1999; vol. 64(6-7); pp. 449-455.
Pauwels, et al., “Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease” Am J. Respir Crit Care Med; 2001; vol. 163; pp. 1256-1276.
Gwilt, et al., “The non-neuronal cholinergic system in the airways: An unappreciated regulatory role in pulmonary inflammation?” Pharmacology & Therapeutics; 2007; pp. 208-222.
Kummer and Lips, “Non-neuronal acetylcholine release and its contribution to COPD pathology” Drug Discovery Today: Disease Mechanisms; 2006; vol. 3; pp. 47-52.
Hohn, et al., “1H-Pyrazolo[3,4-b] pyridines” Journal of Heterocyclic Chemistry; 1972; vol. 9(2); pp. 235-253.
Patel and Malick, “Pharmacological Properties of Tracazolate: A New Non-Benzodiazepine Anxiolytic Agent” European Journal of Pharmacology; 1982; vol. 78; pp. 323-333.
Bare, et al., “Synthesis and Structure-Activity Relationships of a Series of Anxioselective Pyrazolopyridine Ester and Amide Anxiolytic Agents” J. Med. Chem; 1989; vol. 32; pp. 2561-2573.
Denzel, “Neue Synthese 1-unsubstituierter 1H-Pyrazolo [3,4-b] pyridin-5-carbon-saureeser” Archiv der Pharmazie; 1974; vol. 307(3); pp. 177-186.
Ochiai, et al., “New orally active PDE4 inhibitors with therapeutic potential” Bioorganic & Medicinal Chemistry; 2004; vol. 12; pp. 4089-4100.
Ochiai, et al., “Discovery of New Orally Active Phosphodiesterase (PDE4) Inhibitors” Chem. Pharm. Bull.; 2004; vol. 52(9); pp. 1098-1104.
Shi, et al., “Pyrazolopyridines: Effect of Structural Alterations on Activity at Adenosine˜and GABAa-Receptors” Drug Development Research; 1997; vol. 42; pp. 41-56.
Schenone, et al., “Synthesis and Biological Data of 4-Amino-1-(2-chloro-2-phenylethyl)-1H-pyrazolo[3,4-b] pyridine-5-carboxylic Acid Ethyl Esters, a New Series of A1-Adenosine Receptor (A1AR) Ligands” Bioorganic & Medicinal Chemistry Letters; 2001; vol. 11; pp. 2529-2531.
Bondavalli, et al., “Synthesis, Molecular Modeling Studies, and Pharmacological Activity of Selective A1 Receptor Antagonists” 2002; vol. 45; pp. 4875-4887.
De Mello, et al., “Antileishmanial Pyrazolopyridine Derivatives: Synthesis and Structure-Activity Relationship Analysis” J. Med. Chem; 2004; vol. 47; pp. 5427-5432.
Provins, et al., “First dual M3 antagonists-PDE4 inhibitors: Synthesis and SAR of 4,6-diaminopyrimidine derivatives” Bioorganic & Medicinal Chemistry Letters; 2006; vol. 16; pp. 1834-1839.
Provins, et al., “Dual M3 antagonists-PDE4 inhibitors. Part 2: Synthesis and SAR of 3-substituted azetidinyl derivatives” Bioorganic & Medicinal Chemistry Letters; 2007; vol. 17; pp. 3077-3080.
Ochiai, et al., “New orally active PDE4 inhibitors with therapeutic potential” Bioorganic & Medicinal Chemistry Letters; 2004; vol. 14; pp. 29-32.
Daly J. W. et al.; 1-methy1-4-substituted-1H-pyrazolo [3, 4-b] pyridine-5-carboxylic acid derivatives: effect of structural alterations on activity at A1 and A2 adenosine receptors; Medicinal Chemistry Research; 1994; 4(5); pp. 293-306; Birkhaeuser; Boston US.
Callahan James Francis
Lin Guoliang
Wan Zehong
Yan Hongxing
Bernhardt Emily
Glaxo Group Limited
Smith Robert J.
LandOfFree
Dual pharmacophores—PDE4-muscarinic antagonistics does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dual pharmacophores—PDE4-muscarinic antagonistics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dual pharmacophores—PDE4-muscarinic antagonistics will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4260424